Pfizer cancer drug effect may be limited: FDA staff (Reuters)

Reuters – Slower tumor growth in kidney cancer patients taking Pfizer Inc’s experimental drug, Inlyta, in a clinical trial was driven by a subset of patients who are rare in the United States, U.S. Food and Drug Administration researchers said.